Vaccine company Valneva SE (Nasdaq:VALN) (Euronext Paris:VLA) on Tuesday reported positive three-year antibody persistence data for its single-dose chikungunya vaccine, IXCHIQ.

The data demonstrated sustained high levels of neutralising antibodies in both younger and older adults.

These findings confirm the long-lasting protective immunity induced by IXCHIQ, reinforcing its potential to significantly reduce the burden of chikungunya disease.

The IXCHIQ vaccine is currently approved in the United States, Europe and Canada for adults aged 18 and older. Valneva is pursuing label extensions to include adolescents and is working to expand access to the vaccine in low and middle-income countries.